BioMedNewsBreaks Archive - BioMedWire (BMW)

TuesdayApr 15, 2025 3:33 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures $3.7M in Warrant Inducement Transaction

Bluejay (NASDAQ: BJDX) is a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings. The company recently announced its entry into an agreement with institutional investors to exercise existing warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in approximately $3.7 million in gross proceeds. In consideration for the exercise of the existing warrants for cash, the investors received new five-year warrants to purchase the same number of shares at an exercise price of $3.42 per share. Aegis Capital Corp. acted…

TuesdayApr 15, 2025 8:30 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Military Contract Extension for Iridium PTT Services

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, announced that its subsidiary, Global Telesat Communications Ltd., received a one-year contract extension from an African military customer for wireless connectivity services. The renewal builds on a 2024 deal for Iridium Push-To-Talk (PTT) hardware and airtime services, which marked the largest such contract in company history. The extension includes options for additional hardware and annual service renewals and is not impacted by recent U.S. tariffs. The Iridium Extreme PTT devices are favored for their secure, global communication capabilities in high-demand government, military and enterprise applications. To view the full press release, visit:…

MondayApr 14, 2025 3:03 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company today announced interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (“CTCL”). “We are pleased with these recent study results, giving patients an opportunity to access the therapy in an open-label setting,” said Soligenix CEO and President Christopher J. Schaber. “CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet…

MondayApr 14, 2025 1:50 pm

BioMedNewsBreaks – Immunic Inc. (NASDAQ: IMUX) Closes $5.1M Registered Direct

Immunic (NASDAQ: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has closed its previously announced registered direct offering of 5,666,667 shares of its common stock, each at a price of $0.90, led by Aberdeen Investments. Immunic secured approximately $5.1 million in gross proceeds, from which it intends to use the net to fund its clinical trials and operations and for other general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering. To view the full press release, visit…

MondayApr 14, 2025 10:09 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Prevails in Legal Dispute With Former CEO

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative, metabolic and alcohol misuse disorders, announced that a reconsideration motion filed by former CEO Dr. Raza Bokhari was fully dismissed by the Court of Appeal for Ontario. Bokhari, terminated for cause in 2021, had previously lost an arbitration claiming wrongful dismissal, which resulted in a total cost award of approximately C$2.81 million plus interest. Additional court-awarded costs have raised the amount due to over C$3 million. Quantum BioPharma has initiated U.S. collection proceedings, resulting in a judgment entered in its favor by the U.S. District Court for the Eastern District of…

MondayApr 14, 2025 9:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Halts Some U.S. Product Plans in China Over Tariff Escalation

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, announced it will pause select initiatives within its e-commerce development program due to China’s recent tariff hikes on U.S.-produced goods. The affected efforts include the planned launch of the Florida Sunshine brand of vitamins and supplements, which would face high import costs and diminished competitiveness in the Chinese market. The company launched its cross-border program in April 2023 to help U.S. businesses reach Chinese consumers via platforms like Alibaba’s Tmall. Despite the setback, NextPlat will continue offering OPKO Health Europe’s (NASDAQ: OPK) non-U.S.-made products in China, including nutraceuticals, supplements and upcoming pet…

FridayApr 11, 2025 3:30 pm

BioMedNewsBreaks — Adageis Brings Power of AI to the Frontlines of Healthcare

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine (“PRE”) enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization. With streamlined onboarding, projected growth and funding, Adageis is poised for significant expansion in the healthcare technology space, offering investors a compelling opportunity to participate in the evolving $19.27 billion healthcare AI market. To…

FridayApr 11, 2025 8:50 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA™ abuse-deterrent transdermal technology. The patent, titled “Abuse and Misuse Deterrent Transdermal Systems,” was granted on Feb. 11 and recorded in Macao’s Official Bulletin on Mar. 5. This adds to Nutriband’s global IP portfolio, with coverage now spanning 46 countries and both SARs of China. AVERSA is designed to reduce abuse, diversion and accidental exposure of transdermal drugs like opioids. Nutriband is advancing development of AVERSA Fentanyl with partner Kindeva Drug Delivery, aiming to commercialize the world’s first abuse-deterrent fentanyl patch…

ThursdayApr 10, 2025 9:10 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer

Calidi Biotherapeutics (NYSE American: CLDI) has named Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. The appointment comes as Calidi advances clinical development of CLD-201, a virotherapy for solid tumors, following a recently filed Investigational New Drug application. Dr. Clifton brings over 17 years of oncology and clinical trial expertise, including leadership roles at Parthenon Therapeutics and service as a surgical oncologist in the U.S. Army. His extensive experience in immunotherapy is expected to bolster Calidi’s efforts in developing stem cell-based and enveloped virus cancer therapies. To view the full press release, visit: https://ibn.fm/LQkJV About Calidi Biotherapeutics…

WednesdayApr 09, 2025 9:59 am

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Subsidiary Wins UK Government Contract for Satellite Communication Devices

NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd, has secured its first contract with a central UK government department to supply Iridium Push-To-Talk (PTT) satellite communication devices and recurring airtime services. The devices, designed for secure and reliable global communication, will support government staff engaged in policy development and coordination. Initial shipments are scheduled for the second quarter and will not be impacted by recent U.S. tariffs. To view the full press release, visit https://ibn.fm/DJmcP About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures $3.7M in Warrant Inducement Transaction

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Military Contract Extension for Iridium PTT Services

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM)

BioMedNewsBreaks – Immunic Inc. (NASDAQ: IMUX) Closes $5.1M Registered Direct

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Prevails in Legal Dispute With Former CEO

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Halts Some U.S. Product Plans in China Over Tariff Escalation

BioMedNewsBreaks — Adageis Brings Power of AI to the Frontlines of Healthcare

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Subsidiary Wins UK Government Contract for Satellite Communication Devices

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search